


Serial No. 10/598,262

Remarks


Claims 1, 3-8 and 11 are currently pending and claim 16 is withdrawn in the instant application. Applicants submit herewith amendments to the claims and respectfully request entry of these amendments. Presently Applicants amend claim 1, 7, 8 and claim 11, and cancel claims 3-6, and 16, without prejudice to the subject matter therein, reserving the right to pursue withdrawn and/or cancelled subject matter in subsequently filed application(s). After entry of the present amendments, claims 1, 7, 8, and 11 remain in the application.

In the Communication dated December 10, 2009, Claim 11 was rejected under 35 U.S.C. 112, first paragraph. Examiner indicated the rejection could be obviated by deletion of the word "prevention". Claim 11 has been amended to delete the word "prevention", and further amended to clarify that the claims covers both the compounds and salts of Claim 1. In light of this amendment Applicants believe the rejection is moot and submit the claim is now in condition for allowance.

Claim 1 was rejected under 35 U.S.C. 102(b) as anticipated by Fujimura, et al., and Ferrari, et al. The Examiner alleges Fujimura et al. teaches tetralin derivatives which include the




compound, and that this compound anticipates Claim 1. The Examiner further alleges Ferrari et al. teaches β -adrenergic blocking agents including the



compound, and that this compound also anticipates Claim 1. In order to expedite prosecution Applicants submits herewith an amendment to Claim 1 to delete substituents wherein R^1 is $-\text{CH}_2\text{NR}^3\text{R}^4$ or $-\text{CONR}^3\text{R}^4$. Applicants submit this amendment is supported by the examples in the specification as filed. Applicants submit the rejection under 102(b) is moot in light of the present amendment.

Claims 1 and 8 further stand rejected under 35 U.S.C. 103(a) as being obvious over GB 276,571. The Examiner alleges that GB 276,571 teaches aromatic tetrahydronaphthylamines and



derivatives thereof, including the compound, and further alleges this compound renders obvious the aforementioned claims where R^1 is the first choice of claim 1 (which Applicants understand to be $-\text{CH}_2\text{NR}^3\text{R}^4$); R^2 is hydrogen; R^3 is hydrogen; and R^4 is ethyl. Applicants submit the rejection under 103(a) is moot in light of the present amendment to claim 1 which deleted $-\text{CH}_2\text{NR}^3\text{R}^4$ from R^1 .


Claim 7 has been amended to enhance the clarity of the claim. Claim 8 has been amended to clearly indicate that salts of the claimed compounds are included. Examiner objected to claims 3-7 as being dependent upon rejected independent claim 1. In light of the present amendments and

Serial No. 10/598,262

arguments herein, Applicants submit this objection is now moot.

Applicants believe all remaining claims are now in condition and form for allowance, and respectfully request timely examination leading to allowance of all pending claims. The Examiner is invited to contact the undersigned attorney by telephone if he can be of any assistance.

Respectfully submitted,



Dan L. Wood
Attorney/Agent for Applicant(s)
Registration No. 48,613
Phone: 317-277-3366

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
April 9, 2010